胃癌是全球第五大常见癌症，也是癌症相关死亡的第四大常见原因。在化疗或放化疗之前或之后进行手术被认为是局部晚期胃癌的最佳治疗方法。这项研究是来自印度南部一家三级转诊机构的真实世界数据，该机构在四年内治疗胃腺癌并进行了至少两年的随访。这是对患者数据的回顾性分析2015年至2018年肿瘤内科入组的经组织学证实的胃腺癌。本研究收集并分析了胃腺癌患者的人口学详细信息、表现、分期、接受的治疗和结果。总共纳入了488例胃腺癌患者为了研究。患者的分期分布显示早期和局部晚期（45%）和转移性（55%）。腹膜和肝脏是常见的转移部位。这些患者的治疗分布包括围手术期化疗后手术 (25 [5%])、手术后辅助化疗 (65 [13%])、单纯手术 (16 [3%])、围手术期单纯化疗 (23 [4] %]）、姑息化疗（274 [56%]）和支持治疗（85 [17%]）。治愈性、姑息性和支持性治疗的中位总生存期分别为 23 (18-28)、9 (7.6-10.4) 和 4 (2.7-5.3) 个月。初次手术组 (n = 81) 和围手术期化疗组 (n = 66) 意向治疗人群的两年总生存率分别为 67.4% 和 29.9% (p < 0.0001)。胃癌患者的表现性质和治疗完成率较低。治愈患者的中位生存率仍然很低。我国需要探索手术后辅助化疗与围手术期化疗后手术的可治愈胃癌的治疗顺序。© 2023。印度胃肠病学会。

Gastric cancer is the fifth most-common cancer and fourth common cause for cancer-related deaths globally. Surgery preceded or followed by chemotherapy or chemoradiotherapy is considered an optimal treatment for locally advanced gastric cancer. This study is a real-world data from a tertiary referral institute in southern India, in its experience with treating gastric adenocarcinoma over a period of four years with a minimum of two-year follow-up.This was a retrospective analysis of data of patients with histologically proven gastric adenocarcinoma enrolled in the Department of Medical Oncology from 2015 to 2018. The demographic details, presentation, staging, treatment received and outcomes of patients with gastric adenocarcinoma were collected and analyzed in this study.Total 488 patients with gastric adenocarcinoma were included for the study. The stage-wise distribution of patients revealed early and locally advanced (45%) and metastatic (55%). The peritoneum and liver were the common sites of metastasis. The treatment distribution of these patients included perioperative chemotherapy followed by surgery (25 [5%]), surgery followed by adjuvant chemotherapy (65 [13%]), surgery alone (16 [3%]), perioperative chemotherapy alone (23 [4%]), palliative chemotherapy (274 [56%]) and supportive care (85 [17%]). The median overall survival for curative, palliative and supportive treatment was 23 (18-28), nine (7.6-10.4) and four (2.7-5.3) months, respectively. The two-year overall survival in the intention to treat population in the primary surgery (n = 81) and perioperative chemotherapy groups (n = 66) was 67.4% vs. 29.9% (p < 0.0001), respectively.This study highlights the advanced nature of the presentation of gastric cancer patients and the poor rate of treatment completion. The median survival rates in curative patients remain to be dismally poor. The treatment sequence in curable gastric cancer of surgery followed by adjuvant chemotherapy vs. perioperative chemotherapy followed by surgery needs to be explored in our country.© 2023. Indian Society of Gastroenterology.